SuperworthLineage Cell Therapeutics shares outstanding LCTX
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 261.5M
- On a year earlier
- +14.5%
- more shares
Lineage Cell Therapeutics had 261.5M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 14.5% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 237.1M | −1% |
| FY2024 | 239.9M | +37% |
| FY2023 | 175M | +3% |
| FY2022 | 170M | +1% |
| FY2021 | 168.6M | +12% |
| FY2020 | 150.6M | +1% |
| FY2019 | 149.8M | +18% |
| FY2018 | 127M | +2% |
| FY2017 | 124.8M | +21% |
| FY2016 | 102.8M | +24% |
| FY2015 | 83M | +6% |
| FY2014 | 78M | +39% |
| FY2013 | 56.2M | +14% |
| FY2012 | 49.3M | +17% |
| FY2011 | 42.2M | −10% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 261.5M | +15% | |
| Q1 FY26 | 261.2M | +16% | |
| Q4 FY25 | 237.1M | −1% | |
| Q3 FY25 | 228.9M | +21% | |
| Q2 FY25 | 228.4M | +21% | |
| Q1 FY25 | 226.1M | +24% | |
| Q4 FY24 | 239.9M | +37% | |
| Q3 FY24 | 188.8M | +8% | |
| Q2 FY24 | 188.8M | +11% | |
| Q1 FY24 | 182.9M | +8% | |
| Q4 FY23 | 175M | +3% | |
| Q3 FY23 | 174.9M | +3% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Lineage Cell Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.